ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KIT-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KIT-inhibitor
24
trial(s) found.
NCT06578247
Haem
Phase 3
Recruiting
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (
QuANTUM-WILD
)
FLT3 inhibitor
KIT inhibitor
placebo
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05245968
Advanced
Phase 1
Recruiting
A Phase 1 Study of TAS-116 (pimitespib) in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor
BCR-ABL1 inhibitor,first generation
HSP90 inhibitor
KIT inhibitor
PDGFRA inhibitor
Gastrointestinal stromal tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NCT05208047
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors (
CGT9486-21-301
)
KIT D816V inhibitor
KIT inhibitor,first generation
KIT inhibitor,type 1
PDGFR inhibitor
VEGFR inhibitor
Gastrointestinal stromal tumour
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04996875
Haem
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (
CGT9486-20-201
)
KIT D816V inhibitor
KIT inhibitor,type 1
Haematological malignancy
Mast cell leukaemia
Systemic mastocytosis
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
NCT04925648
Advanced
Phase 2
Recruiting
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (
PICASSO
)
AR-targeted agent,next generation
AR-targeted agent,second generation
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Darolutamide
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
cancer therapy
cancer therapy,AR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
endocrine therapy
endocrine therapy,androgen axis-targeting
+ KIT inhibitor
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04910685
Haem
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (
BLU-263-1201
)
KIT D816V inhibitor
placebo
Systemic mastocytosis
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ KIT/PDGFR/RET/VEGFR inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03970447
Advanced
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000532505
Advanced
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623001338651
Haem
Phase 2
Recruiting
CML14 (ASCENDANCE) - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (
CML14-ASCENDANCE
)
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
Chronic myelogenous leukaemia
ACTRN12621000611820
Advanced
Phase 2
Recruiting
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (
PICAASO
)
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
cancer therapy
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
+ KIT inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12620000849998
Advanced
Phase 1 / Phase 2
OLD TRIAL
A phase I/II, open label, multi-centre study to assess the safety, tolerability, and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments.
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
FLT3 inhibitor
KIT inhibitor
PDGFR inhibitor
VEGFR inhibitor
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12619001655134
Haem
Phase 2
Recruiting
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (
INTERVENE
) Acute Myeloid Leukaemia
BCL2 inhibitor
+ KIT inhibitor
Acute myeloid leukaemia
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05425940
Advanced
Phase 3
Active not recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (
STELLAR-303
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
MET/VEGFR2/AXL/MER inhibitor
anti-PD-L1 monoclonal antibody
Colorectal cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05328908
Advanced
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer (
RELATIVITY-123
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Tipiracil Hydrochloride
Trifluridine
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
Colorectal adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05198934
Advanced
Phase 3
Active not recruiting
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (
CodeBreak300
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05186753
Haem
Phase 2
Active not recruiting
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with Nonadvanced Systemic Mastocytosis (
CGT9486-21-202
)
KIT D816V inhibitor
KIT inhibitor,type 1
placebo
Systemic mastocytosis
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03685448
Advanced
Phase 2
Unknown
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802) (
UNICAB
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
NCT02773524
Advanced
Phase 3
Unknown
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) (
INTEGRATEIIa
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
placebo
Gastroesophageal cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Active not recruiting (4)
Unknown (3)
Enrolling by invitation (1)
OLD TRIAL
paused (1)
Status unknown (1)
Recruitment Country and State
NSW (18)
VIC (15)
QLD (11)
SA (11)
WA (5)
NZ (3)
ACT (1)
NT (1)
TAS (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Phase 2 (8)
Phase 2 / Phase 3 (2)
Phase 3 (9)
Trial Type
Advanced (18)
Haem (6)
Cancer Therapy Class
KIT
100%
VEGFR
67%
PDGFR
58%
RET
42%
PD-1/PD-L1
29%
VEGFR2
29%
MET
25%
FGFR
25%
FGFR1
25%
FGFR1/2/3
25%
FGFR2
25%
FGFR3
25%
FGFR4
25%
AXL
21%
PD-1
21%
BCR-ABL1
21%
PDGFRA
21%
FLT3
17%
ROS1
17%
SRC
17%
YES1
17%
LAG3
13%
MER
8%
AR
8%
androgen axis
8%
TIGIT
8%
PI3K
8%
mTOR
8%
mTORC1
8%
mTORC2
8%
CRAF
8%
RAF
8%
PD-L1
8%
EGFR
8%
HIF2a
4%
HSP90
4%
ERBB2
4%
HPK1
4%
OX40
4%
PARP
4%
VEGF
4%
VEGFR1
4%
VEGFR3
4%
PI3K-delta
4%
PI3Kalpha
4%
BCL2
4%
HDAC
4%
PKC
4%
HRAS G12C
4%
KRAS
4%
KRAS G12C
4%
NRAS G12C
4%
CYP17A1
4%
ALK
4%
ATR
4%
CDK4
4%
CDK6
4%
JAK1
4%
JAK2
4%
SMO
4%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (7)
5042 - Bedford Park - Flinders Medical Centre (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
2109 - North Ryde - Macquarie University Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2640 - Albury - Border Medical Oncology Research Unit (4)
2031 - Randwick - Prince of Wales Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
2139 - Concord - Concord Repatriation General Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
5037 - Glandore - Ashford Cancer Centre (2)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2217 - Kogarah - St George Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
4032 - Chermside - The Prince Charles Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2485 - Tweed Heads - The Tweed Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Urogenital cancer
Gastrointestinal cancer
Kidney cancer
Leukaemia
Clear cell renal cell carcinoma
Upper gastrointestinal cancer
Mast cell disorder
Systemic mastocytosis
Colorectal cancer
Lower gastrointestinal cancer
Non-clear cell renal cell carcinoma
Gastrointestinal stromal tumour
Male genital cancers
Prostate cancer
Myeloid leukaemia
Mast cell leukaemia
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Sarcoma
Chronic leukaemia
Chronic myelogenous leukaemia
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Acute myeloid leukaemia
Colorectal adenocarcinoma
Chromophobe renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
Differentiated thyroid carcinoma
Endocrine gland cancer
Thyroid cancer
Gastroesophageal cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy